Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers

Rosalyn D. Blumenthal(Center for Molecular Medicine and Immunology), David M. Goldenberg(Unknown)

BMC Cancer

January 3, 2007

10.1186/1471-2407-7-2

Cited by 273

Related Papers

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

|New England Journal of Medicine|2019|846

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

|Oncotarget|2015|464

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

|Journal of Clinical Oncology|2017|407

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

|Annals of Oncology|2021|371

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

|Clinical Cancer Research|2015|344